Keiretsu Forum Hosts Successful Investor Conferences, Attracting Over 150 Investors

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Dec 11 2025

0mins

MDBH-4.16%

Should l Buy MDBH?

Source: Globenewswire

Investor Gathering: The Southeast Investor Conference and Mid-Atlantic Investor Summit attracted over 150 accredited investors and family offices, fostering in-depth discussions on early-stage capital and developing pathways for higher-quality deal flow.
Significant Outcomes: The Atlanta conference featured 75 investors and over 20 presentations, showcasing 10 actively funding companies, which significantly boosted investor confidence and engagement in the market.
Exit Strategy Optimization: The Philadelphia summit emphasized disciplined portfolio strategies and time-to-exit, proposing structured financing and 'restart' strategies to shorten exit timelines, thereby enhancing investor return expectations.
Future Outlook: Keiretsu Forum plans to continue its Investor Summit series in 2026, expecting to attract more local innovation-stage startups and further drive the development of the regional investment ecosystem.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MDBH?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MDBH

About MDBH

MDB Capital Holdings, LLC is a holding company that has three subsidiaries: MDB CG Management Company (MDB Management), Public Ventures, LLC (Public Ventures), and PatentVest, Inc. (PatentVest), and has a partner company, MDB Minnesota One, Inc. Its segments include broker dealer & intellectual property service, and technology development. The broker dealer & intellectual property service segment has two subsidiaries, Public Ventures and PatentVest. Public Ventures is a full-service broker dealer firm focusing on conducting private and public securities offerings. PatentVest offers in-depth patent research used for investment banking due diligence. The technology development segment includes MDB Minnesota One, Inc., a research and development stage company that is developing a small molecule senescence platform. MDB Management is an administrative entity whose purpose is to conduct, and wherever possible, to consolidate shared services/resources, for its United States-based operations.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Analysis of Oral Small-Molecule GLP-1 Drug Competition

5 days agoNewsfilter

Significant Market Potential: The injectable GLP-1 drug market has reached $71 billion but covers less than 5% of eligible patients, indicating a vast 95% market potential for oral small-molecule drugs, presenting substantial future growth opportunities.
Patent Portfolio Disparities: An analysis of over 1,200 patent documents reveals dramatic disparities in patent depth among programs at similar development stages, which will significantly impact their market competitiveness and long-term viability.
Scarcity of Partnership Opportunities: Since 2023, over $47 billion in GLP-1-related deal value has been committed, yet most oral programs remain unpartnered, highlighting potential opportunities and risks in market consolidation.
Importance of Patent Protection: With the patent cliffs for semaglutide and tirzepatide approaching, possessing broad patent protection will determine which assets can dominate the market and which may face early generic competition.

MDB Capital Appoints New Board Member

Feb 03 2026Newsfilter

Board Changes: MDB Capital Holdings announced the appointment of Jeb Terry to its Board of Directors while expressing gratitude to Susanne Meline for her contributions, effective February 1, 2026, reflecting the company's ongoing commitment to leadership optimization.
New Board Member Background: Jeb Terry brings over 20 years of investment experience in microcap medical and biotechnology sectors, having founded Aberdeen Investment Management with a focus on undervalued opportunities in life sciences, which is expected to provide MDB with valuable industry insights.
Strategic Implications: The addition of the new board member is seen as a crucial step for MDB in expanding its founder and investor community, with CEO Christopher Marlett emphasizing that Terry's expertise will aid the company's further development in public venture capital.
Future Outlook: MDB Capital remains committed to driving the growth of innovative companies through its unique public venture capital platform, focusing on early public offerings and follow-on financings to support promising enterprises.